{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:09:25Z","timestamp":1788340165677,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1023\/b:ddas.0000034568.69407.47","type":"journal-article","created":{"date-parts":[[2004,7,13]],"date-time":"2004-07-13T22:48:50Z","timestamp":1089758930000},"page":"1036-1039","source":"Crossref","is-referenced-by-count":68,"title":["Fecal Lactoferrin: A New Parameter to Monitor Infliximab Therapy"],"prefix":"10.1007","volume":"49","author":[{"given":"Stephan","family":"Buderus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Boone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lyerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lentze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"492767_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","volume":"109","author":"HM Van Dullemen","year":"1995","unstructured":"Van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol-ogy 109:129\u2013135, 1995","journal-title":"Gastroenterol-ogy"},{"key":"492767_CR2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group: Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359:1541\u20131549, 2002","journal-title":"Lancet"},{"issue":"1","key":"492767_CR3","first-page":"92","volume":"137","author":"JS Hyams","year":"2000","unstructured":"Hyams JS, Markowitz J, Wyllie R: Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 137(1):92\u201396, 2000","journal-title":"J Pediatr"},{"key":"492767_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","volume":"98","author":"R Baldassano","year":"2003","unstructured":"Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter H: Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 98:833\u2013838, 2003","journal-title":"Am J Gastroenterol"},{"key":"492767_CR5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398\u20131405, 1999","journal-title":"N Engl J Med"},{"key":"492767_CR6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G D'haens","year":"1999","unstructured":"D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endo-scopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116:1029\u20131034, 1999","journal-title":"Gastroenterology"},{"key":"492767_CR7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1572-0241.2003.07458.x","volume":"98","author":"SV Kane","year":"2003","unstructured":"Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB: Fecal lactoferrin is a sensitive and specific marker in the diagnosis of chronic inflammatory bowel disease. Am J Gastroenterol 98:1309\u20131314, 2003","journal-title":"Am J Gastroenterol"},{"key":"492767_CR8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1572-0241.2002.05470.x","volume":"97","author":"M Kayazawa","year":"2002","unstructured":"Kayazawa M, Saitoh O, Kojima K, Nakawaga K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K: Lactoferrin in whole gut lavage as a marker for disease activity in inflammatory bowel disease. Am J Gastroenterol 97:360\u2013369, 2002","journal-title":"Am J Gastroenterol"},{"key":"492767_CR9","first-page":"A","volume":"122","author":"S Buderus","year":"2002","unstructured":"Buderus S, Lentze MJ, Boone J, Lyerly D: Fecal lactoferrin: Sen-sitive marker for monitoring pediatric patients with inflammatory bowel disease. Gastro 122:A-219, 2002","journal-title":"Gastro"},{"key":"492767_CR10","first-page":"439","volume":"12","author":"JS Hyams","year":"1991","unstructured":"Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, Michener WM, Levy JS, Lesser ML: Development and validation of a pedi-atric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12:439\u2013447, 1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"492767_CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70173-3","volume":"116","author":"A Otley","year":"1999","unstructured":"Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffith AM: Assessing activity of pediatric Crohn's disease: Which index to use? Gastroenterology 116:527\u2013531, 1999","journal-title":"Gastroenterology"},{"key":"492767_CR12","first-page":"742","volume":"246","author":"TR Walker","year":"2003","unstructured":"Walker TR, Sandborn WJ, Boone J, Lyerly D, Rufo P: Fecal lacto-ferrin measurements are useful in the interval assessment of pa-tients with active and inactive IBD. Am J Gastroenterol 98:S 246:742, 2003","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000034568.69407.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:DDAS.0000034568.69407.47\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000034568.69407.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:49:12Z","timestamp":1753760952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:DDAS.0000034568.69407.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["492767"],"URL":"https:\/\/doi.org\/10.1023\/b:ddas.0000034568.69407.47","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}